Strategic Partners

Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therapy, Allogene is well-positioned to further the potential of allogeneic cell therapy for patients.

"We have built mutual trust and respect over the years in the CAR T industry and this collaboration will be the starting point for a long-term partnership. Our mission at Allogene is to catalyze the next revolution in cancer treatment through the development of allogeneic CAR T therapies directed at blood cancers as well as solid tumors. We believe this collaboration fuels our mission and we look forward to partnering with Cellectis to accelerate the development of allogeneic cell therapies.”

David Chang, M.D., Ph.D., President and Chief Executive Officer of Allogene

Servier is the leading French independent pharmaceutical company. Cellectis and Servier are collaborating on five targets, including UCART19, with ongoing pediatric and adult trials sponsored by Servier in the UK.

"Collaborating closely with Cellectis on UCART19, an innovative cellular therapy candidate against lymphoid malignancies, Servier’s team constantly explores new horizons and delivers the utmost best of their expertise. Together, our highly complementary competencies and know-how give our teams the best chances of providing patients worldwide with a new generation of cancer treatments they need."

                Olivier Laureau, President of Servier

World-Class Clinical Centers

Weill Cornell Medicine, NewYork-Presbyterian Hospital, was ranked in 2016 as New York’s No. 1 hospital for the 16th year in a row, and No. 6 ranked hospital in the United States.

Cellectis is closely working with Weill Cornell Medicine on the development of UCART123 for Acute Myeloid Leukemia (AML).

The Phase 1 clinical trial with UCART123 in patients with AML is coordinated by principal investigator Prof. Gail J. Roboz, MD, at Weill Cornell Medicine and Director of the Clinical and Translational Leukemia Programs at Weill Cornell Medicine and NewYork-Presbyterian.

MD Anderson Cancer Center is ranked the No. 1 hospital for cancer care in the nation by U.S. News & World Report’s “Best Hospitals” survey.

Cellectis and MD Anderson are developing UCART123 for both AML and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), as well as UCART22 for B-cell acute lymphoblastic leukemia (B-ALL) in adults.

The UCART123 clinical program for BPDCN is led by Dr. Naveen Pemmaraju, MD, Assistant Professor, and Professor Hagop Kantarjian, MD, Chairman in the Department of Leukemia and University Chair in Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston. The UCART123 clinical program for AML is led by Prof. Hagop Kantarjian and Dr. Naveen Pemmaraju as well.

The UCART22 clinical program for B-ALL will be led by Dr. Nitin Jain, Assistant Professor, and Prof. Hagop Kantarjian.

Exclusive License

The University of Minnesota granted Cellectis an exclusive license to TALEN® gene editing technology. TALEN® enables the ability to rethink how we treat diseases altogether. Cells can be engineered with optimized features for cancer therapies, drug discovery, gene function studies, industrial biotechnology and more.